Abstract
Get full access to this article
View all access options for this article.
References
1.Sixth BioSpectrum-ABLE Biotech Industry Survey , Vol. 6 , 2008 , p. 9 .
2.
Cukier
K. N.
‘Navigating the Future(s) of Biotech Intellectual Property’ . Nature Biotechnology , Vol. 24 , 2006 , pp. 249 –251 .
3.
Hubbard
T.
Love
J.
‘A New Trade Framework for Global Healthcare R&D’ . PLoS Biology , Vol. 2 , 2004 , pp. 147 –150 .
4.
Mehdiratta
R.
Parida
D. K.
Saberwal
G.
, ‘Bio-business in Brief: The Challenges of Clinical Trials’ . Current Science , Vol. 93 , 2007 , pp. 1367 –1375 .
5.
Munos
B.
‘Can Open-Source R&D Reinvigorate Drug Research?’ Nature Reviews Drug Discovery 5 , 2006 , pp. 723 –729 .
6.
Nathan
C.
‘Aligning Pharmaceutical Innovation with Medical Need’ Nature Medicine , Vol. 13 , 2007 , pp. 304 –308 .
7.
Parida
D. K.
Mehdiratta
R.
Saberwal
G.
, ‘How Many Patents Does a Bio-therapeutics Company Need'? Nature Biotechnology , Vol. 26 , 2008 , pp. 763 –766 .
8.
Thiers
F. A.
Sinskey
A. J.
Berndt
E. R.
‘Trends in the Globalization of Clinical Trials’ . Nature Reviews Drug Discovery , Vol. 7 , 2008 , pp. 13 –14 .